Leiden, Netherlands
Leiden, Netherlands

Leiden University, located in the city of Leiden, is the oldest university in the Netherlands. The university was founded in 1575 by William, Prince of Orange, leader of the Dutch Revolt in the Eighty Years' War. The royal Dutch House of Orange-Nassau and Leiden University still have a close relationship. The Queens Juliana and Beatrix and crown-prince Willem-Alexander studied at Leiden University. In 2005 Queen Beatrix received a rare honorary degree from Leiden University. Wikipedia.


Time filter

Source Type

Patent
Leiden University | Date: 2016-04-14

The present invention is based on the finding that microRNA from the microRNA gene cluster located on the human chromosomal at locus 14q32 play an important role in vascular development and re-modelling. Modulators of any of the 14q32 microRNA may be exploited as a means to modulate vascular re-modelling processes and/or in the treatment and/or prevention of vascular disorders or disease.


Patent
Academisch Medisch Centrum and Leiden University | Date: 2017-02-01

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido- deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (X) on the methyloxy- carbon. Formula (I), Formula (Ia). These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay- Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.


Patent
Leiden University | Date: 2017-03-29

The present invention relates to novel compounds which are selective inhibitors of diacylglycerol lipase alpha and beta. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by increased 2-arachidonoylglycerol levels. Diacylglycerol lipase-a (alternative name: Snl-specific diacylglycerol hydrolase a; DAGL-a) and - are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. Selective and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion. The inventive compounds are in particular suitable for the treatment of neurodegenerative diseases, inflammatory diseases, drug abuse and impaired energy balance, such as obesity, wherein X1 is -CH-, -CF- or -N-.


Patent
Fred Hutchinson Cancer Research Center, University of Rochester and Leiden University | Date: 2017-01-25

Embodiments provide methods and compositions related to determining or predicting the presence or risk of developing DUX-4-related diseases such as muscular dystrophy. In particular, methods and compositions may be provided by identifying patients with Facioscapulohumeral muscular dystrophy (FSHD). Methods and compositions are based, in part, on the discovery that expression of certain biomarkers in patients or subjects can determine the presence or risk of developing DUX-4-related diseases such as muscular dystrophy, or particularly FSHD. Further disclosed are DUX-4 biomarkers that can be used for the methods.


Patent
Leiden University and Janssen Pharmaceutical | Date: 2016-12-19

The present invention stems from the finding that two genes designated R2R^(1 )and R2R^(2), play important roles in tissue development and cancer biology. In particular, the inventors have discovered that these two genes are expressed in pulmonary cells and are required for late branching morphogenesis of pulmonary epithelium and endothelium and support the development/maintenance of the refined three dimensional architecture of the lung. These genes are essential in the squamous differentiation program and development/maintenance of the progenitor (Krt14 expressing) cell pool. Moreover, the inventors have identified crucial roles for these genes in cancer biology, particularly processes associated with the acquisition of an immortal and metastatic phenotype (including cancer progression and metastasis) and pulmonary and cardiac development. Accordingly, the invention provides compounds and methods for use in the treatment of cardiac and pulmonary diseases and well as in cancer.


Patent
Fred Hutchinson Cancer Research Center, Leiden University and University of Rochester | Date: 2017-07-19

The invention provides an agent capable of inhibiting or suppressing the level of DUX4-fl expression in a population of cells in a mammalian subject, for use in a method of treating a mammalian subject suffering from, or at risk for developing, Facioscapulohumeral Dystrophy (FSHD), wherein the agent is a nucleic acid.


Timp J.F.,Leiden University
Blood | Year: 2013

Cancer-associated venous thrombosis is a common condition, although the reported incidence varies widely between studies depending on patient population, start and duration of follow-up, and the method of detecting and reporting thrombotic events. Furthermore, as cancer is a heterogeneous disease, the risk of venous thrombosis depends on cancer types and stages, treatment measures, and patient-related factors. In general, cancer patients with venous thrombosis do not fare well and have an increased mortality compared with cancer patients without. This may be explained by the more aggressive type of malignancies associated with this condition. It is hypothesized that thromboprophylaxis in cancer patients might improve prognosis and quality of life by preventing thrombotic events. However, anticoagulant treatment leads to increased bleeding, particularly in this patient group, so in case of proven benefit of thromboprophylaxis, only patients with a high risk of venous thrombosis should be considered. This review describes the literature on incidence of and risk factors for cancer-associated venous thrombosis, with the aim to provide a basis for identification of high-risk patients and for further development and refinement of prediction models. Furthermore, knowledge on risk factors for cancer-related venous thrombosis may enhance the understanding of the pathophysiology of thrombosis in these patients.


Beenakker C.W.J.,Leiden University
Reviews of Modern Physics | Year: 2015

The theory of random matrices originated half a century ago as a universal description of the spectral statistics of atoms and nuclei, dependent only on the presence or absence of fundamental symmetries. Applications to quantum dots (artificial atoms) followed, stimulated by developments in the field of quantum chaos, as well as applications to Andreev billiards - quantum dots with induced superconductivity. Superconductors with topologically protected subgap states, Majorana zero modes, and Majorana edge modes, provide a new arena for applications of random-matrix theory. These recent developments are reviewed, with an emphasis on electrical and thermal transport properties that can probe the Majorana fermions. © 2015 American Physical Society. © 2015 American Physical Society.


Marijnen C.A.M.,Leiden University
The Lancet Oncology | Year: 2015

Improved treatment strategies have eliminated local control as the major problem in rectal cancer. With increasing awareness of long-term toxic effects in survivors of rectal cancer, organ-preservation strategies are becoming more popular. After chemoradiotherapy, both watchful waiting and local excision are used as possible alternatives for radical surgery. Although these seem attractive strategies, many issues about the safety of organ preservation remain. Additionally, radiotherapy strategies are mainly aimed at intermediate and high-risk rectal tumours, and adaptation of this standard practice for a completely new treatment indication has yet to start. This Review will discuss the options and problems of organ preservation, and address the research questions that need to be answered in the coming years, with a specific focus on radiotherapy. © 2015 Elsevier Ltd.


Beenakker C.W.J.,Leiden University
Annual Review of Condensed Matter Physics | Year: 2013

Majorana fermions (particles that are their own antiparticle) may or may not exist in nature as elementary building blocks, but in condensed matter they can be constructed out of electron and hole excitations. What is needed is a superconductor to hide the charge difference and a topological (Berry) phase to eliminate the energy difference from zero-point motion. A pair of widely separated Majorana fermions, bound to magnetic or electrostatic defects, has non-Abelian exchange statistics. A qubit encoded in this Majorana pair is expected to have an unusually long coherence time. I discuss strategies to detect Majorana fermions in a topological superconductor, as well as possible applications in a quantum computer. The status of the experimental search is reviewed. © 2013 by Annual Reviews. All rights reserved.

Loading Leiden University collaborators
Loading Leiden University collaborators